Navigation Links
Improvement in Prediction of Blood Clots in Cancer Patients
Date:9/9/2010

WASHINGTON, Sept. 9 /PRNewswire-USNewswire/ -- For cancer patients, who have an increased risk of developing venous thromboembolism (VTE) due to a hyperactive blood coagulation system, there is now an enhanced risk model to predict their chance of developing blood clots, according to a recent study published today in Blood, the journal of the American Society of Hematology. VTE, the formation of blood clots in the veins, develops in up to 20 percent of cancer patients and is one of the leading causes of death among this patient population. Patients with hematologic malignancies (blood cancers), particularly those with lymphoma and multiple myeloma, have relatively high rates of VTE—results from this study found that 7.2 percent of lymphoma patients and 7.4 percent of the total study population developed VTE, compared to an estimated general population incidence rate of .001 percent(1)

"Because the risk of VTE is not equal in all cancer patients and anticoagulation in cancer patients results in a higher risk of bleeding complications, categorizing cancer patients according to their VTE risk is important," said Ingrid Pabinger, MD, professor at the Medical University of Vienna and lead author of the study. Patients with high risk of VTE may benefit from routine thrombophrophylaxis, preventive treatment for blood clotting, while low-risk patients tend to have a higher bleeding risk and may not be the best candidates for routine anticoagulation treatments.

Although there is a current risk prediction model for VTE in cancer patients, which includes factors such as site of cancer, body mass index, platelet and leukocyte counts, and hemoglobin level—all known to increase the risk of cancer-associated VTE—the new model also incorporates two new biomarkers, soluble P-selectin (sP-selectin) and D-dimer, to further stratify patients into high- and low-risk groups. sP-selectin is a cell adhesion molecule that promotes blood clot formation and D-dimer is a protein found in the blood that is used to detect abnormal blood clot formation and breakdown. Both have been previously identified as predictive biomarkers for cancer-associated VTE and their addition into the risk prediction model improves the accuracy of the classification of the patients into different risk categories. According to this new risk scoring model, about one-third (35 percent) of cancer patients in the highest risk category developed VTE during the study, as opposed to only one percent of patients in the lowest risk category.

In this study, researchers examined 819 cancer patients enrolled in the Vienna Cancer and Thrombosis Study (CATS), an ongoing prospective observational study performed at the Medical University of Vienna, between October 2003 and December 2008. Cancer types included: brain, breast, lung, stomach, colorectal, pancreatic, kidney, prostate, and hematologic malignancies such as myeloma and lymphoma.

"Our expanded model demonstrates that cancer patients at a very high risk of VTE can be defined more precisely," said Cihan Ay, MD, hematology fellow at the Clinical Division of Hematology and Hemostaseology at the Medical University of Vienna and co-author of the study. "This new model can help clinicians tailor their anticoagulant therapy and improve blood clotting prevention, which will maximize the clinical benefit and cost-effectiveness of disease prevention and minimize the risk of bleeding complications."

(1)Office of the Surgeon General. Surgeon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. Available at: http://www.surgeongeneral.gov/topics/deepvein/

The American Society of Hematology is the world's largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology. ASH provides Blood: The Vital Connection, a credible online resource addressing bleeding and clotting disorders, anemia, and cancer. The official journal of ASH is Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online.


'/>"/>
SOURCE American Society of Hematology
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GeneLink Reports Second Quarter Improvement
2. Drug Study Shows Improvement in Major Orthopedic Surgery Care
3. Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months
4. Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010
5. Study Data Show INTUNIV™ (guanfacine) Extended Release Tablets Co-administered With Stimulants Provided ADHD Symptom Improvement in Children and Adolescents
6. Renhuang Pharmaceuticals Announces Continual Improvement in Days Sales Outstanding
7. Garnet BioTherapeutics Announces First Patient Treated in Trial of New Therapy for Improvement in Scar Appearance
8. PARI Pharmas Altera Delivers Gileads Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa
9. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
10. AstraZeneca Offers Online Enrollment and Additional Improvements to Patient Assistance Program
11. Solos Endoscopy, Inc. Makes Significant Design Improvement To Its MammoView(TM) Ductoscope
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... and PITTSBURGH, Feb. 10, 2016 Mylan N.V. (NASDAQ, ... quarter and year ended December 31, 2015. ... Full year adjusted total revenues of $9.45 billion, up ... year; GAAP total revenues of $9.43 billion. Excluding the ... markets specialty and branded generics business (the "EPD Business"), ...
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, ... transformative new approaches to the treatment of lupus ... of a multiple ascending dose study in patients ... compound RSLV-132. --> ... placebo-controlled multiple ascending dose study of RSLV-132 in ...
(Date:2/10/2016)... , Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC ... a 1-for-100 reverse split of its issued and outstanding ... trading on Thursday, February 11, 2016. The Company,s common ... CUSIP number 76303T308 and temporary ticker symbol "RCHAD". After ... under the ticker symbol (RCHA).  --> ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... LaserShip, a regional parcel carrier that services the ... Eastern Michigan last Friday in order to aid in the Flint water crisis. In ... a facility located in Clio, only 15 miles away from Flint. , “We have ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand ... within Healthcare, recently partnered with Heart City Health Center to improve ... 23 years, Heart City Health Center has provided the Elkhart community with access ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... 10 ... Brand. There were three leading bottled water brand owners that topped the list as ... enhance connectivity and optimize conversion. The premier brand was Tibet 5100, a top notch ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... welcomes S.S. Nesbitt as the latest addition to its growing list of Partner ... locations throughout the Southeast, from Orlando to Huntsville and in between. , Harnessing ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are challenged to ... shows that the Goal Attainment Scale (GAS) captures 20% more change in outcomes ... more about the Goal Attainment Scale, Education Resources Inc. is offering a course ...
Breaking Medicine News(10 mins):